Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Ogluo can be used for the treatment of severe hypoglycaemic episodes while GlucaGen is out of stock, as per SPS guidance; however Ogluo is not suitable for treatment of beta blocker or other drug overdoses

Oglue can be used for the treatment of severe hypoglycaemic episodes for paediatric patients weighing under 25 kg while GlucaGen is out of stock - as per SPS guidance

Acute herpetic keratitis (dendritic and geographic ulcers) Instil one drop of gel in the eye to be treated, 5 times a day until complete corneal re-epithelialisation. Then 3 instillations a day for 7 days after healing. Treatment does not usually exceed 21 days. 1. Manufacturer advises women of childbearing potential should use effective contraception during treatment; men should be advised to use barrier contraception during and for at least 90 days after treatment. 2. Manufacturer advises that use in children under 18 years is not recommended since no specific studies have been conducted

The Dexcom ONE + CGM device replaces the Dexcom ONE - Please note - a separate transmitter is not required. Commissioned for all people (both adults and children) with type 1 diabetes who have been assessed by their specialist to meet the prevailing CIOS ICB criteria.

Commissioned for all people (both adults and children) with type 1 diabetes who have been assessed by their specialist to meet the prevailing CIOS ICB criteria. This product will be replacing the Freestlye Libre 2 from July 2024. Please note this is a 15 day sensor

Only to be prescribed in primary care following a request from the RCHT diabetes team for people with type 1 diabetes alongside the mylife Ypsopump and CamAPS FX (MyLife) algorithm as part of a hybrid closed loop (HCL) system. May also be requested by secondary care teams for use as part of a hybrid closed-loop system in pregnancy in line with NICE TA943. Not to be prescribed as a standalone CGM. This product will be replacing the freestyle libre 3 from Dec 2025. Please note this is a 15 day sensor.

Note the potential for dosing errors due to the way the sialanar strength is expressed. Sialanar contains 400mcg/ml of glycopyrronium bromide. This is equivalent to 320mcg/ml of glycopyrronium. Therefore glycopyrronium bromide 400mcg/ml oral solution sugar free is the same as sialanar 320mcg/ml oral solution

For type 1 pump patients only. Not for initiation in primary care